Rivfloza Injection, Solution
Product Images NDC 0169-5307

57 FDA label images from Novo Nordisk · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 57 technical images submitted to the FDA as part of the official labeling for Rivfloza (NDC 0169-5307). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Structural_formula (Structural Formula)

Structural_formula (Structural Formula)
Chemical structure diagram of nedosiran depicting the nucleotide sequence and detailed molecular representations of its modified nucleotides, including indicated substitutions and chemical groups for both sense (passenger) and antisense (guide) strands.*
FDA Label Image

Figure_1 (Figure 1)

Figure_1 (Figure 1)
A line chart depicting percent change from baseline over study visits from baseline to day 180. Two treatment groups are compared: RIVFLOZA (N=23) represented by a solid line with diamond markers, showing a decreasing trend in percent change, and placebo (N=12) represented by a dashed line with square markers, showing values fluctuating around zero. Error bars indicate variability at each time point.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph depicting percent change from baseline over time (days 0 to 180) in a patient group receiving RIVFLOZA (nedosiran). The y-axis shows percent change from baseline, ranging roughly from 20 to -80 percent. Data points at several visits include Day 30, 60, 90, 120, 150, and 180 (EOS). The number of patients is shown for each visit, ranging from 13 to 15. Error bars indicate variability at each time point.*
FDA Label Image

Image_03 (Image 03)

Image_03 (Image 03)
An illustration showing the parts of a RIVFLOZA 128 mg/0.8 mL injection syringe labeled for subcutaneous use. Components labeled include needle cap, medicine in barrel, rubber stopper, finger grip, and plunger rod.*
FDA Label Image

Image_04 (Image 04)

Image_04 (Image 04)
An illustrated diagram of the RIVFLOZA (nedosiran) 160 mg/mL prefilled injection syringe. The diagram labels key parts of the syringe including the needle cap, medicine in barrel, rubber stopper, finger grip, and plunger rod. The image highlights the 160 mg/mL strength for subcutaneous injection.*
FDA Label Image

Image-5 (Image 01)

Image-5 (Image 01)
An instructional illustration showing a RIVFLOZA pre-filled syringe for subcutaneous injection, labeled with the drug name nedosiran. The image also includes icons for an alcohol wipe, cotton balls or gauze, and a sharps disposal container, indicating required supplies for the injection process.*
FDA Label Image

Image_06 (Image 05)

Image_06 (Image 05)
An illustration of a RIVFLOZA (nedosiran) injection pen for subcutaneous use, labeled with parts including needle cap, barrel, finger grip, and plunger rod. The image highlights the pen components used for administering the solution injection.*
FDA Label Image

Image_07 (Image 06)

Image_07 (Image 06)
An instructional illustration showing the parts of a RIVFLOZA (nedosiran) subcutaneous injection syringe. Labeled components include the needle cap removed, barrel, finger grip, and plunger rod, indicating the key elements of the injection device.*
FDA Label Image

Image_08 (Image 07)

Image_08 (Image 07)
An instructional illustration showing three items: an alcohol wipe packet, a cotton ball or gauze, and a red sharps disposal container. These items are typically used for safe subcutaneous injection procedures and proper disposal of needles.*
FDA Label Image

Image_09 (Image 08)

Image_09 (Image 08)
An instructional illustration showing how to locate the expiration date on the packaging of RIVFLOZA injection solution. The expiration date is indicated on a tab or flap on the box, labeled as 'EXP YYYY-MM-DD.'*
FDA Label Image

Image_10 (Image 09)

Image_10 (Image 09)
Illustration showing a closed box on a countertop with a clock icon above it indicating a 30-minute wait time, likely indicating a step to wait for 30 minutes after an action related to the product.*
FDA Label Image

Image_11 (Image 10)

Image_11 (Image 10)
An instructional illustration showing a hand gripping the barrel of a prefilled syringe, with an upward green arrow indicating the direction to pull or remove the syringe from its packaging.*
FDA Label Image

Image_12 (Image 11)

Image_12 (Image 11)
An illustration showing a syringe prefilled with Rivfloza (nedosiran) injection solution, highlighting the color of the solution inside the syringe as colorless to yellow. The syringe label includes the drug name, indication for monthly subcutaneous injection, and usage instructions.*
FDA Label Image

Image_13 (Image 12)

Image_13 (Image 12)
An instructional diagram showing recommended injection sites for RIVFLOZA (nedosiran) subcutaneous injection. The highlighted areas for injection are the stomach area and the upper thighs on a front view outline of a human figure.*
FDA Label Image

Image_14 (Image 13)

Image_14 (Image 13)
An instructional illustration showing a hand holding a small cloth or wipe, gently pressing it on the skin, likely to clean the injection site before administering a subcutaneous injection.*
FDA Label Image

Image_15 (Image 14)

Image_15 (Image 14)
An instructional illustration showing hands removing and discarding the cap from a syringe, with an arrow indicating the cap should be thrown away, likely part of preparation instructions for the RIVFLOZA injection.*
FDA Label Image

Image_16 (Image 15)

Image_16 (Image 15)
An instructional illustration showing how to hold and insert a prefilled syringe at a 45-degree angle using a finger grip. It depicts one hand stabilizing the injection site while the other hand holds the syringe for subcutaneous injection.*
FDA Label Image

Image_17 (Image 16)

Image_17 (Image 16)
An instructional diagram showing the removal of the rubber stopper from a syringe by pulling the plunger rod at a 45-degree angle. The diagram highlights the plunger rod and rubber stopper with arrows and labels, demonstrating proper technique for preparing an injection.*
FDA Label Image

Image_18 (Image 17)

Image_18 (Image 17)
Instructional illustration showing the proper technique for subcutaneous injection at a 45-degree angle into the skin. The second part depicts cleaning the injection site with an antiseptic wipe before administration.*
FDA Label Image

Image_19 (Image 18)

Image_19 (Image 18)
An instructional illustration showing a hand disposing of a syringe into a red sharps disposal container. The syringe is held above the open container, and a downward arrow indicates proper disposal direction. Text labels identify the sharps disposal container.*
FDA Label Image

Flip-arrow (Flip Arrow)

FDA Label Image

Pull-out-arrow (Pull Out Arrow)

Pull-out-arrow (Pull Out Arrow)
An instructional illustration showing a black triangle arrow pointing upward above the text 'PULL OUT,' indicating an action typically related to removing or pulling out a component from packaging or device.*
FDA Label Image

Image_20 (Image 19)

FDA Label Image

Image_21 (Image 20)

FDA Label Image

Image_22 (Image 21)

FDA Label Image

128-160-2 (128 160 2)

128-160-2 (128 160 2)
The image shows two color-coded labels indicating available strengths of RIVFLOZA (nedosiran) injection, solution for subcutaneous use. The first label, in dark teal, displays 128 mg/0.8 mL, and the second, in orange, shows 160 mg/mL. Both correspond to strengths supplied by Novo Nordisk.*
FDA Label Image

Flip-arrow-1 (Flip Arrow 01)

FDA Label Image

80-mg-vial (80 mg Vial)

80-mg-vial (80 mg Vial)
RIVFLOZA 80 mg/0.5 mL subcutaneous injection solution vial label showing the product strength and a small vial image, labeled by Novo Nordisk.*
FDA Label Image

Image_25 (Image 24)

Image_25 (Image 24)
An instructional diagram showing components and setup for RIVFLOZA injection. It illustrates one or two 1 mL syringes with attached 27-gauge ½-inch needles, labeling parts such as needle cap, barrel, rubber stopper, finger grip, and plunger rod. Also shows one or two vials of RIVFLOZA medication, with the note that each carton contains one vial.*
FDA Label Image

Image_26 (Image 25)

Image_26 (Image 25)
An instructional illustration showing three items for injection preparation and disposal: an alcohol wipe packet labeled 'Alcohol Wipe,' a cotton ball or gauze pad image, and a red sharps disposal container. These items are typically used for subcutaneous injection procedures.*
FDA Label Image

Image_27 (Image 26)

Image_27 (Image 26)
Illustration showing the parts of a syringe containing RIVFLOZA (nedosiran) injection, solution. The syringe components labeled include the needle cap, barrel, rubber stopper, finger grip, and plunger rod. The image indicates one or two 1 mL syringes with attached 27-gauge 1/2 inch needles for subcutaneous administration.*
FDA Label Image

Image_28 (Image 27)

Image_28 (Image 27)
An illustration showing three items related to injection safety: a packet labeled 'Alcohol wipes', cotton balls or gauze, and a red sharps disposal container. Each item is labeled underneath the image.*
FDA Label Image

Image_29 (Image 28)

Image_29 (Image 28)
Instructional illustration showing a two-step process: verifying the expiration date on a box labeled 'EXP YYYY-MM-DD', and setting a timer or wait period of 30 minutes after placing the box on a surface.*
FDA Label Image

Image_30 (Image 29)

Image_30 (Image 29)
An instructional illustration showing a hand inserting a vial into a device or holder, indicated by a green arrow guiding the vial downward. The image likely demonstrates part of the preparation or assembly process for a RIVFLOZA injection device or syringe.*
FDA Label Image

Image_31 (Image 30)

Image_31 (Image 30)
An illustration of a clear vial with a blue cap containing a liquid solution. An arrow points to the liquid inside, labeled as "Colorless to yellow," indicating the acceptable color range of the solution.*
FDA Label Image

Image_32 (Image 31)

Image_32 (Image 31)
Diagram illustrating recommended injection sites for RIVFLOZA (nedosiran) subcutaneous injection. Highlighted areas include the stomach area and upper thighs on a human figure, indicating preferred locations for administering the injection.*
FDA Label Image

Image_33 (Image 32)

Image_33 (Image 32)
An instructional illustration showing a hand holding a small rectangular alcohol prep pad or wipe, positioned near skin to demonstrate cleaning or disinfecting the injection site for a subcutaneous injection.*
FDA Label Image

Image_34 (Image 33)

Image_34 (Image 33)
An instructional illustration showing a hand holding a vial with the thumb pushing on the vial's blue cap, indicated by a green arrow pointing upward. The image likely demonstrates how to access or prepare the vial for use, related to the subcutaneous injection of RIVFLOZA (nedosiran).*
FDA Label Image

Image_35 (Image 02)

Image_35 (Image 02)
An instructional illustration showing a hand placing a small patch or label on the top of a vial with a rubber stopper, likely demonstrating a step in preparing a subcutaneous injection or medication vial handling.*
FDA Label Image

Image_36 (Image 34)

Image_36 (Image 34)
Illustration showing a pair of hands preparing a subcutaneous injection by pulling the cap off a needle attached to a syringe, indicated by green arrows demonstrating the direction to remove the cap. The image is instructional, likely related to the preparation of RIVFLOZA (nedosiran) injection solution.*
FDA Label Image

Image_37 (Image 35)

Image_37 (Image 35)
An instructional illustration showing a syringe needle inserted into a vial for medicine extraction, followed by a depiction of a hand holding the syringe and vial with an arrow indicating the direction for pressing or extracting medication. The image includes a note to keep the tip of the needle in the medicine while drawing.*
FDA Label Image

Image_38 (Image 36)

Image_38 (Image 36)
An instructional illustration showing two hands holding a syringe vertically with the needle capped. The image emphasizes the proper handling or preparation technique, indicated by green vibration lines around the syringe barrel.*
FDA Label Image

Image_39 (Image 37)

Image_39 (Image 37)
An instructional illustration showing a syringe needle positioned above a vial. A green arrow points upward from the vial toward the needle, indicating the action of drawing medication from the vial into the syringe.*
FDA Label Image

Image_40 (Image 38)

Image_40 (Image 38)
An instructional illustration showing a hand holding a syringe for subcutaneous injection at a 45-degree angle while the other hand pinches the skin. The image demonstrates proper injection technique likely related to the administration of RIVFLOZA (nedosiran) injection solution.*
FDA Label Image

Image_41 (Image 39)

Image_41 (Image 39)
An instructional illustration showing the correct technique for subcutaneous injection using a syringe. It depicts a hand holding a syringe at a 45-degree angle with labels pointing to the plunger rod and rubber stopper. The diagram highlights the angle and hand position for administration.*
FDA Label Image

Image_42 (Image 40)

Image_42 (Image 40)
Instructional illustration showing the subcutaneous injection technique for RIVFLOZA (nedosiran injection). The image depicts positioning the syringe at a 45-degree angle to the skin for injection, followed by applying a cotton ball to the injection site after administering the dose.*
FDA Label Image

Image_43 (Image 41)

Image_43 (Image 41)
An instructional illustration showing two syringes being placed into a sharps disposal container. A hand is depicted holding one syringe above the container, indicating proper disposal of injectable materials.*
FDA Label Image

Flip-arrow-2 (Flip Arrow 02)

FDA Label Image

Pull-out-arrow-2 (Pull Out Arrow 01)

Pull-out-arrow-2 (Pull Out Arrow 01)
An instructional illustration consisting of a black triangle arrow pointing upward above the text 'PULL OUT'. This image likely indicates a step or action to remove or pull out a component of the packaging or product.*
FDA Label Image

Image_44 (Image 42)

FDA Label Image

Image_45 (Image 43)

FDA Label Image

Image_46 (Image 44)

FDA Label Image

80-mg-vial-2 (80 mg Vial 01)

80-mg-vial-2 (80 mg Vial 01)
Label showing a 80 mg/0.5 mL strength for RIVFLOZA (nedosiran) injection, solution. The label includes a small illustration of a vial with a blue cap on a white background alongside the strength information on a blue background.*
FDA Label Image

Flip-arrow-3 (Flip Arrow 03)

FDA Label Image

Sleeve_128mg (Sleeve 128mg)

Sleeve_128mg (Sleeve 128mg)
The image shows the packaging label for Rivfloza (nedosiran) injection, 128 mg/0.8 mL, a subcutaneous injection. The label indicates the product is a sterile single-dose pre-filled syringe with a quantity of 0.8 mL. It is manufactured by Pyramid Laboratories for Dicerna Pharmaceuticals, a Novo Nordisk company, and distributed by Novo Nordisk Inc.*
FDA Label Image

Sleeve_160mg (Sleeve 160mg)

Sleeve_160mg (Sleeve 160mg)
Packaging label for Rivfloza (nedosiran) injection 160 mg/mL by Dicerna, a Novo Nordisk company. The label indicates a 1 mL sterile single-dose pre-filled syringe for subcutaneous injection only. It includes usage warnings and storage instructions, as well as distributor information for Novo Nordisk.*
FDA Label Image

Sleeve_80mg (Sleeve 80mg)

Sleeve_80mg (Sleeve 80mg)
Rivfloza (nedosiran) injection 80 mg/0.5 mL subcutaneous injection vial packaging label. The label shows the product name, strength, dosage form as injection solution, subcutaneous route, and contains dosing instructions, warnings, and manufacturing details. It is labeled Rx only and manufactured by Dicerna, a Novo Nordisk company.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.